Agios Pharmaceuticals price to sales ratio AGIO

Market value divided by revenue over the last twelve months, since 2014.

Today, Oct 23, 2026: 22.5×
9-year median: 42.2×
Against its 9-year history: 26th; percentile: 0 is its lowest day, 100 its highest
9-year range: 11.8× to 136×
Peer median: 2.0×

Agios Pharmaceuticals' price to sales ratio is 22.5× as of Oct 23, 2026.

That is below its 9-year median of 42.2×, lower than on 74% of days in the last 9 years.

Over that time it ranged from 11.8× in Dec 2020 to 136× in Jun 2018.

The median for 10 large drugmakers of a similar size is 2.0×.

Price to sales ratio over time

median 42.2×

The dashed line is the 9-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	22.5×	18.2×	38.2×
2025	36.5×	31.8×	62.6×
2024	57.9×	50.5×	107×
2023	51.8×	49.2×	97.5×
2022	n/m a value too high to mean anything
2021	15.2×	15.2×	19.9×
2020	15.4×	11.8×	30.9×
2019	25.4×	17.6×	43.8×
2018	35.5×	33.5×	136×
2017	n/m a value too high to mean anything
2016	n/m a value too high to mean anything
2015	55.9×	53.7×	70.0×
2014	51.7×	43.9×	65.8×

Against its peers

Companies in Drug Manufacturers - General nearest Agios Pharmaceuticals' size, closest first, today.

Company	Price to sales ratio
AGIOAgios Pharmaceuticals	22.5×
PBHPrestige Consumer Healthcare	2.0×
HRMYHarmony Biosciences	2.2×
NRIXNurix Therapeutics	3.9×
ANIPANI Pharmaceuticals	1.7×
PAHCPhibro Animal Health	1.0×
ANABAnaptysbio	n/m
PCRXPacira BioSciences	1.9×
OGNOrganon	0.6×
LQDALiquidia	8.5×
ARQTArcutis Biotherapeutics	8.5×
Peer median	2.0×

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Agios Pharmaceuticals

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.